Musi waChikunguru 5, Novo Nordisk yakatanga chirongwa chechitatu chekiriniki yekuyedza yeCagriSema jekiseni muChina, chinangwa chayo chiri kuenzanisa kuchengetedzeka uye kushanda kwejekiseni reCagriSema ne semeglutide muvarwere vakafuta uye vakafuta muChina.
CagriSema jekiseni ndeyekureba-inobata musanganiswa kurapa pasi pekuvandudzwa neNovo Nordisk, izvo zvikuru zvinoriumba GLP-1 (glucagon-like peptide-1) receptor agonist smeglutide uye yakareba-inobata amylin analog cagrilintide.CagriSema jekiseni rinogona kupihwa pasi peganda kamwe pasvondo.
Chinangwa chikuru chaive chekuenzanisa CagriSema (2.4 mg / 2.4 mg) ne semeglutide kana placebo kamwe vhiki nevhiki subcutaneously.Novo Nordisk yakazivisa mhedzisiro yekuyedzwa kweCagriSema kurapwa kwechikamu chechipiri chirwere cheshuga, izvo zvakaratidza kuti CagriSema's hypoglycemic effect iri nani pane iyo semeglutide, uye ingangoita 90% yezvidzidzo vakawana HbA1c chinangwa.
Iyo data yakaratidza kuti kuwedzera kune yakakosha hypoglycemic effect, maererano nekurasikirwa kwehuremu, CagriSema jekiseni yakanyanyisa kupfuura semeglutide (5.1%) uye cagrilintide (8.1%) nekurasikirwa kwe15.6%.
Mushonga wekuvandudza Tirzepatide ndiyo yekutanga kubvumidzwa vhiki nevhiki GIP/GLP-1 receptor agonist.Inosanganisa mhedzisiro yeaviri incretins mune imwe molecule inobaiwa kamwe chete pasvondo uye iri kirasi nyowani yekurapa kwerudzi rwechipiri chirwere cheshuga.Tirzepatide yakatenderwa neUS Food and Drug Administration (FDA) muna Chivabvu 2022 kuvandudza glycemic control (pakudya uye kurovedza muviri) muvakuru vane Type 2 chirwere cheshuga uye parizvino yakatenderwa muEuropean Union, Japan nedzimwe nyika.
Musi waChikunguru 5, Eli Lilly akazivisa chikamu chechitatu SURPASS-CN-MONO chidzidzo chekunyoresa kukiriniki yekiriniki yekiriniki uye yekuzivisa ruzivo chikuva chekurapa chirwere cheshuga chechipiri.SURPASS-CN-MONO inongoitika, kaviri-mapofu, placebo-inodzorwa chikamu III chidzidzo chakagadzirirwa kuongorora kushanda uye kuchengetedzwa kwetirzepatide monotherapy kana ichienzaniswa ne placebo muvanhu vane Type 2 chirwere cheshuga.Chidzidzo ichi chakaronga kubatanidza varwere ve200 vane Type 2 chirwere cheshuga vanga vasiri pamishonga yeantidiabetic mumazuva makumi mapfumbamwe asati ashanyira 1 (kunze kwemamwe mamiriro ekiriniki, akadai sehurwere, kuchipatara, kana kuvhiyiwa kwakasarudzwa, kwenguva pfupi (≤14). mazuva) kushandiswa kwe insulin).
Type 2 chirwere cheshuga chinotarisirwa kubvumidzwa gore rino
Mwedzi wapfuura, mhedzisiro yeSURPASS-AP-Combo kudzidza yakabudiswa May 25 mu blockbuster magazine Nature Medicine.Mhedzisiro yacho yakaratidza kuti kana ichienzaniswa ne insulin glargine, Tirzepatide yakaratidza zvirinani HbA1c uye kuderera kwehuremu muhuwandu hwevarwere vane chirwere cheshuga cherudzi rwechipiri mudunhu reAsia-Pacific (kunyanya China): HbA1c kuderedzwa kusvika 2.49% uye kuderera kwehuremu hunosvika 7.2 kg. (9.4%) pamavhiki e40 ekurapwa, kuvandudzwa kukuru kweropa lipids neropa, uye kuchengetedzwa kwese uye kushivirira kwaive kwakanaka.
Iyo Phase 3 yekiriniki yekuyedza yeSURPASS-AP-Combo ndiyo yekutanga ongororo yeTirzepatide yakaitwa kunyanya muChina varwere vane Type 2 chirwere cheshuga, ichitungamirwa naProfessor Ji Linong wePeking University People's Hospital.SURPASS-AP-Combo inopindirana nemhedzisiro yepasi rose SURPASS yakatevedzana yekutsvagisa, iyo zvakare inoratidza kuti pathophysiology yechirwere cheshuga muvarwere veChinese inopindirana neiyo yevarwere vepasirese, inova hwaro hwekutsvagisa pamwe nekuvandudzwa kwemishonga mitsva. muChina nepasirese, uye inopawo humbowo hwakasimba hutsigiro hwekupa varwere veChinese mukana wekushandisa mishonga yekurapa chirwere cheshuga ichangoburwa uye kukiriniki kwavo kuChina nekukurumidza sezvinobvira.
Nguva yekutumira: Sep-18-2023